Ignite Creation Date:
2024-05-06 @ 3:55 PM
Last Modification Date:
2024-10-26 @ 2:00 PM
Study NCT ID:
NCT04808297
Status:
COMPLETED
Last Update Posted:
2022-04-11
First Post:
2021-03-02
Brief Title:
Trehalose in Subjects With Neuronal Ceroid Lipofuscinoses
Sponsor:
IRCCS Fondazione Stella Maris
Organization:
IRCCS Fondazione Stella Maris
Study Overview
Official Title:
A Study in Subjects With Neuronal Ceroid Lipofuscinoses Taking Trehalose
Status:
COMPLETED
Status Verified Date:
2022-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
3AL-CLN36
Brief Summary:
Neuronal Ceroid Lipofuscinoses NCL or Battens disease are the most common juvenile neurodegenerative disease characterized by early blindness movement disorders cognitive and behavioral impairment epilepsy and retinopathy
This study aims to collect clinical and laboratory data of patients with NCL taking Trehalose
This study aims to collect clinical and laboratory data of patients with NCL taking Trehalose
Detailed Description:
This study aims to collect clinical and laboratory data of patients with NCL taking Trehalose
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None